Gilead Sciences surprised investors with stronger-than-expected Q2 results, driven by a surge in its HIV portfolio. The biotech giant reported earnings of $2.01 per share, beating estimates, while revenue climbed to $7.1 billion—a $200 million year-over-year increase. The standout performer was its newly approved twice-yearly HIV prevention injection, Lenacapavir, which saw rapid adoption, contributing to a 7% growth in HIV segment sales ($5.1 billion). Management raised full-year guidance, projecting adjusted earnings of $7.95–$8.25 per share and revenue of $28.3–$28.7 billion, sending shares up nearly 3% in after-hours trading.
Mixed Performance Across Divisions
While the HIV business thrived, cell therapies declined 7% to $485 million amid stiff competition. Oncology drug Trodelvy grew 14% to $364 million, offsetting some weakness in hepatitis C treatments. Despite conservative 2025 forecasts aligning with analyst expectations, Gilead’s stock has gained 46% over the past year, reflecting investor confidence in its HIV innovation pipeline.
Ad
Gilead Sciences Stock: Buy or Sell?! New Gilead Sciences Analysis from February 7 delivers the answer:
The latest Gilead Sciences figures speak for themselves: Urgent action needed for Gilead Sciences investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Gilead Sciences: Buy or sell? Read more here...
